Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vyne Therapeutics Inc (VYNE)

Vyne Therapeutics Inc (VYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,138
  • Shares Outstanding, K 33,286
  • Annual Sales, $ 570 K
  • Annual Income, $ -26,480 K
  • EBIT $ -30 M
  • EBITDA $ -31 M
  • 60-Month Beta 2.00
  • Price/Sales 49.55
  • Price/Cash Flow N/A
  • Price/Book 0.62
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.50
  • Most Recent Earnings $-0.17 on 11/06/25
  • Next Earnings Date 03/05/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.28
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5503 +9.94%
on 02/11/26
0.6080 -0.49%
on 03/02/26
+0.0338 (+5.92%)
since 02/02/26
3-Month
0.3520 +71.88%
on 12/15/25
0.7500 -19.33%
on 12/17/25
+0.2473 (+69.14%)
since 12/02/25
52-Week
0.2805 +115.69%
on 09/09/25
2.6024 -76.75%
on 03/03/25
-1.9150 (-75.99%)
since 02/28/25

Most Recent Stories

More News
Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , Dec. 18, 2025 /PRNewswire/ -- The Ademi Firm is investigating VYNE (Nasdaq: VYNE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

VYNE : 0.6050 (+0.77%)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)

NEW YORK , Dec. 17, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders...

VYNE : 0.6050 (+0.77%)
VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

VYNE : 0.6050 (+0.77%)
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement 

Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for Graves’ disease...

VYNE : 0.6050 (+0.77%)
VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update

Company is progressing its previously initiated strategic review evaluating a range of options to maximize shareholder value, including assessment of internal pipeline opportunities and broader strategic...

VYNE : 0.6050 (+0.77%)
VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated...

VYNE : 0.6050 (+0.77%)
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from...

VYNE : 0.6050 (+0.77%)
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

VYNE : 0.6050 (+0.77%)
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

VYNE : 0.6050 (+0.77%)
VYNE Therapeutics Provides Update on VYN202 Program

VYNE : 0.6050 (+0.77%)

Business Summary

VYNE Therapeutics Inc. focuses on developing and commercializing therapeutics for dermatology. The company's product pipeline consist FMX103 and FCD105 which are in clinical stage. VYNE Therapeutics Inc., formerly known as Menlo Therapeutics Inc., is based in Bridgewater, New Jersey.

See More

Key Turning Points

3rd Resistance Point 0.6221
2nd Resistance Point 0.6151
1st Resistance Point 0.6100
Last Price 0.6050
1st Support Level 0.5979
2nd Support Level 0.5909
3rd Support Level 0.5858

See More

52-Week High 2.6024
Fibonacci 61.8% 1.7154
Fibonacci 50% 1.4414
Fibonacci 38.2% 1.1675
Last Price 0.6050
52-Week Low 0.2805

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar